Evidence map›Paper›PMID 36072559›Full record

ArticleIn silico pharmacology2022

Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.

Santosh Kumar Maurya, Homa Fatma, Akhilesh Kumar Maurya, Nidhi Mishra, Hifzur R Siddique

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Pyrogallol fromInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Santosh Kumar MauryaMolecular Cancer Genetics and Translational Research Laboratory, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh, 202002 UP India.
Homa Fatma *Molecular Cancer Genetics and Translational Research Laboratory, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh, 202002 UP India.
Akhilesh Kumar MauryaChemistry Laboratory, Department of Applied Sciences, Indian Institute of Information Technology Allahabad, Prayagraj, 211015 UP India.
Nidhi MishraChemistry Laboratory, Department of Applied Sciences, Indian Institute of Information Technology Allahabad, Prayagraj, 211015 UP India.
Hifzur R SiddiqueMolecular Cancer Genetics and Translational Research Laboratory, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh, 202002 UP India.ORCID 0000-0001-8736-0487
Aligarh Muslim University · INIndian Institute of Information Technology Allahabad · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (CaP) is one of the most frequent malignancies amongst men. Enzalutamide is the second-generation potent androgen receptor (AR) antagonist used against metastatic and non-metastatic CaP. Unfortunately, the development of chemoresistance in cancer cells reduces the effectiveness of Enzalutamide. Lupeol is a pentacyclic triterpene found in different fruits, vegetables, and medicinal plants and possesses anti-inflammatory and anti-cancer properties. Here, we report in silico and in vitro studies of Lupeol and Enzalutamide against the β-CATENIN, c-FLIP Graphical abstract:

Indexed as

Cancer stem cellsChemoresistanceChemosentizationEnzalutamideLupeolProstate cancer

Identifiers

PMID36072559
PMCPMC9441409
OpenAlexW4294716489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.